TP53 and hepatocellular carcinoma: Moreover, the cell cycle pathway was more frequently altered in HBV-related HCC, mainly via inactivating mutations of TP53 (41% in HBV versus 16% in other etiologies) and IRF2, these two mutations being mutually exclusive [27].